Current Report Filing (8-k)
June 13 2022 - 5:08PM
Edgar (US Regulatory)
0001455365
false
0001455365
2022-06-10
2022-06-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 10, 2022
Cognition
Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40886 |
|
13-4365359 |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification No.) |
2500 Westchester Avenue
Purchase, NY |
|
10577 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (412) 481-2210
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Exchange on Which
Registered |
Common Stock, par value $0.001
per share |
|
CGTX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 10, 2022, Cognition Therapeutics, Inc. (the “Company”)
held its Annual Meeting of Stockholders (the “Annual Meeting”). The following is a brief description of the final
voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting.
Proposal 1 – Election of Class I Directors. Each of Peggy
Wallace and Ellen B. Richstone were elected to the Board of Directors as Class I directors to serve until the Company’s 2025 Annual
Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement,
disqualification or removal as follows:
Name |
|
For |
|
Withheld |
|
Broker Non-Votes |
Peggy Wallace |
|
9,933,410 |
|
386,494 |
|
2,894,756 |
Ellen B. Richstone |
|
10,242,608 |
|
77,296 |
|
2,894,756 |
Proposal 2 – Ratification of Independent Registered Public
Accountants. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the
2022 fiscal year was ratified, as follows:
For |
|
Against |
|
Abstentions |
|
Broker Non-Votes |
13,202,020 |
|
9,545 |
|
3,095 |
|
0 |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
COGNITION THERAPEUTICS, INC. |
Date: June 13, 2022 |
|
|
|
By: |
/s/ Lisa Ricciardi |
|
Name: |
Lisa Ricciardi |
|
Title: |
President and Chief Executive Officer |
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024